v3.26.1
Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Series A Non-Voting Convertible Preferred Stock
Series A Non-Voting Convertible Preferred Stock
Preferred Stock
Series B Non-Voting Convertible Preferred Stock
Series B Non-Voting Convertible Preferred Stock
Preferred Stock
Series B Non-Voting Convertible Preferred Stock
Common Stock
Beginning balance, preferred stock (in shares) at Dec. 31, 2024             346,000   17,000  
Beginning balance at Dec. 31, 2024 $ 517,804 $ 13 $ 1,334,223 $ 180 $ (972,432)   $ 146,425   $ 9,395  
Beginning balance, common stock (in shares) at Dec. 31, 2024   60,257,000                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)   19,000                
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan 218   218              
Stock-based compensation expense 8,859   8,859              
Foreign currency translation adjustment 14     14            
Unrealized (loss) gain on marketable securities 488     488            
Net loss (44,773)       (44,773)          
Ending balance, preferred stock (in shares) at Mar. 31, 2025             346,000   17,000  
Ending balance at Mar. 31, 2025 482,610 $ 13 1,343,300 682 (1,017,205)   $ 146,425   $ 9,395  
Ending balance, common stock (in shares) at Mar. 31, 2025   60,276,000                
Beginning balance, preferred stock (in shares) at Dec. 31, 2024             346,000   17,000  
Beginning balance at Dec. 31, 2024 517,804 $ 13 1,334,223 180 (972,432)   $ 146,425   $ 9,395  
Beginning balance, common stock (in shares) at Dec. 31, 2024   60,257,000                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Foreign currency translation adjustment (22)                  
Unrealized (loss) gain on marketable securities 296                  
Net loss (81,490)         $ (15,078)   $ (726)    
Ending balance, preferred stock (in shares) at Jun. 30, 2025             346,000   17,000  
Ending balance at Jun. 30, 2025 455,773 $ 13 1,353,408 454 (1,053,922)   $ 146,425   $ 9,395  
Ending balance, common stock (in shares) at Jun. 30, 2025   60,373,000                
Beginning balance, preferred stock (in shares) at Mar. 31, 2025             346,000   17,000  
Beginning balance at Mar. 31, 2025 482,610 $ 13 1,343,300 682 (1,017,205)   $ 146,425   $ 9,395  
Beginning balance, common stock (in shares) at Mar. 31, 2025   60,276,000                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)   97,000                
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan 730   730              
Stock-based compensation expense 9,378   9,378              
Foreign currency translation adjustment (36)     (36)            
Unrealized (loss) gain on marketable securities (192)     (192)            
Net loss (36,717)       (36,717) $ (6,791)   $ (327)    
Ending balance, preferred stock (in shares) at Jun. 30, 2025             346,000   17,000  
Ending balance at Jun. 30, 2025 455,773 $ 13 1,353,408 454 (1,053,922)   $ 146,425   $ 9,395  
Ending balance, common stock (in shares) at Jun. 30, 2025   60,373,000                
Beginning balance, preferred stock (in shares) at Dec. 31, 2025           346,045 346,000 16,667 17,000  
Beginning balance at Dec. 31, 2025 $ 715,236 $ 15 1,686,167 869 (1,127,635)   $ 146,425   $ 9,395  
Beginning balance, common stock (in shares) at Dec. 31, 2025 78,189,811 78,190,000                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs (in shares)   296,000                
Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs $ 9,747   9,747              
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)   354,000                
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan 3,663   3,663              
Stock-based compensation expense 12,806   12,806              
Unrealized (loss) gain on marketable securities (1,636)     (1,636)            
Net loss (69,005)       (69,005)          
Ending balance, preferred stock (in shares) at Mar. 31, 2026             346,000   17,000  
Ending balance at Mar. 31, 2026 670,811 $ 15 1,712,383 (767) (1,196,640)   $ 146,425   $ 9,395  
Ending balance, common stock (in shares) at Mar. 31, 2026   78,840,000                
Beginning balance, preferred stock (in shares) at Dec. 31, 2025           346,045 346,000 16,667 17,000  
Beginning balance at Dec. 31, 2025 $ 715,236 $ 15 1,686,167 869 (1,127,635)   $ 146,425   $ 9,395  
Beginning balance, common stock (in shares) at Dec. 31, 2025 78,189,811 78,190,000                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Foreign currency translation adjustment $ 0                  
Unrealized (loss) gain on marketable securities (3,265)                  
Net loss (105,205)         $ (15,147)   $ (701)    
Ending balance, preferred stock (in shares) at Jun. 30, 2026           346,045 346,000 0 0  
Ending balance at Jun. 30, 2026 $ 1,101,141 $ 16 2,189,936 (2,396) (1,232,840)   $ 146,425   $ 0  
Ending balance, common stock (in shares) at Jun. 30, 2026 88,064,133 88,064,000                
Beginning balance, preferred stock (in shares) at Mar. 31, 2026             346,000   17,000  
Beginning balance at Mar. 31, 2026 $ 670,811 $ 15 1,712,383 (767) (1,196,640)   $ 146,425   $ 9,395  
Beginning balance, common stock (in shares) at Mar. 31, 2026   78,840,000                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Conversion of Series B Non-Voting Convertible Preferred Stock to common Stock (in shares)                 (17,000) 667,000
Conversion of Series B Non-Voting Convertible Preferred Stock to common stock 0   9,395           $ (9,395)  
Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs (in shares)   7,475,000                
Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs 434,898 $ 1 434,897              
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)   1,083,000                
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan 19,749   19,749              
Stock-based compensation expense 13,512   13,512              
Foreign currency translation adjustment 0                  
Unrealized (loss) gain on marketable securities (1,629)     (1,629)            
Net loss (36,200)       (36,200) $ (5,052)   $ (225)    
Ending balance, preferred stock (in shares) at Jun. 30, 2026           346,045 346,000 0 0  
Ending balance at Jun. 30, 2026 $ 1,101,141 $ 16 $ 2,189,936 $ (2,396) $ (1,232,840)   $ 146,425   $ 0  
Ending balance, common stock (in shares) at Jun. 30, 2026 88,064,133 88,064,000